In recent years, Antibody-Drug Conjugates (ADCs) have emerged as a promising therapeutic approach for the treatment of various types of cancer. An ADC consists of three key components: an antibody that targets a specific tumor antigen, a cytotoxin or payload, and a cleavable or uncleavable linker that connects the payload to the antibody. The specificity of the target recognition and the potency of the toxin make ADCs a veritable "magic bullet". These "magic bullets" deliver highly targeted and potent treatment, attacking cancerous cells throughout the body while sparing healthy cells from harm. The rational selection of targets, antibodies, linkers, payloads, their combinations, and conjugation methods are crucial for effective treatment.
Of these components, target selection, linker selection, conjugation methods, and evaluating preclinical/clinical efficacy are considered critical factors in the development of ADCs. Download now to learn more.